We are live on
!
Find out more
FO
FT Options Portfolio holdings
AUM
$66.4M
1-Year Est. Return
18.48%
This Fund
S&P 500
This Quarter
Est. Return
+24.92%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$126M
AUM Growth
+$9.73M
(+8.4%)
Cap. Flow
+$224M
Cap. Flow
% of AUM
177.31%
Top 10 Holdings %
Top 10 Hldgs %
37.67%
Holding
493
New
153
Increased
113
Reduced
67
Closed
127
Top Buys
| 1 |
Procter & Gamble
PG
|
+$3.82M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$2.47M |
| 3 |
iShares Biotechnology ETF
IBB
|
+$2M |
| 4 |
Ulta Beauty
ULTA
|
+$1.86M |
| 5 |
MON
Monsanto Co
MON
|
+$1.82M |
Top Sells
| 1 |
MDVN
MEDIVATION, INC.
MDVN
|
+$7.18M |
| 2 |
Biogen
BIIB
|
+$4.33M |
| 3 |
Cal-Maine
CALM
|
+$3.64M |
| 4 |
Apple
AAPL
|
+$2.74M |
| 5 |
ALR
Alere Inc
ALR
|
+$2.22M |
Sector Composition
| 1 | Healthcare | 39.95% |
| 2 | Consumer Staples | 5.72% |
| 3 | Consumer Discretionary | 5.14% |
| 4 | Technology | 3.35% |
| 5 | Materials | 2.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Regeneron Pharmaceuticals
REGN
$70.9B
| $10.8M | 8.6% |
26,988
-4,366
| -14% | -$1.75M |
|
2
Abbott
ABT
$175B
| $6.41M | 5.08% |
151,635
+24,383
| +19% | +$1.04M |
|
|
3
PUT
Regeneron Pharmaceuticals
REGN
$70.9B
| $5.69M | 4.51% |
74,300
+27,300
| +58% | +$11M |
|
|
GWPH
4
CALL
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $5.16M | 4.09% |
131,100
+1,300
| +1% | +$124K |
|
|
5
Procter & Gamble
PG
$349B
| $4.04M | 3.2% |
45,000
+44,000
| +4,400% | +$3.82M |
|
|
6
Bristol-Myers Squibb
BMY
$124B
| $3.96M | 3.14% |
73,537
+38,462
| +110% | +$2.47M |
|
7
Akebia Therapeutics
AKBA
$359M
| $3.31M | 2.63% |
366,118
-1,158
| -0.3% | -$9.84K |
|
8
Sarepta Therapeutics
SRPT
$1.82B
| $3.01M | 2.39% |
49,025
-11,883
| -20% | -$359K |
|
|
CLVS
9
DELISTED
Clovis Oncology, Inc.
CLVS
| $2.56M | 2.03% |
71,091
+65,901
| +1,270% | +$1.41M |
|
|
OTIC
10
DELISTED
Otonomy, Inc.
OTIC
| $2.53M | 2.01% |
139,085
-53,700
| -28% | -$878K |
|
|
11
iShares Biotechnology ETF
IBB
$9.23B
| $2.03M | 1.61% |
+21,000
| New | +$2M |
|
|
ICPT
12
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $2.01M | 1.6% |
78,500
+58,300
| +289% | +$9.19M |
|
|
MON
13
DELISTED
Monsanto Co
MON
| $1.77M | 1.4% |
+17,313
| New | +$1.82M |
|
|
14
Ulta Beauty
ULTA
$20.6B
| $1.75M | 1.39% |
+7,362
| New | +$1.86M |
|
15
Humana
HUM
$48B
| $1.65M | 1.3% |
9,300
+1,450
| +18% | +$252K |
|
|
POT
16
DELISTED
Potash Corp Of Saskatchewan
POT
| $1.55M | 1.23% |
95,080
-1,000
| -1% | -$16.5K |
|
|
ICPT
17
PUT
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $1.53M | 1.21% |
12,900
| – | – |
|
|
CASC
18
DELISTED
Cascadian Therapeutics, Inc.
CASC
| $1.5M | 1.19% |
152,929
-33,348
| -18% | -$236K |
|
19
Rocket Pharmaceuticals
RCKT
$376M
| $1.49M | 1.18% |
39,216
+3,028
| +8% | +$95.2K |
|
20
Teva Pharmaceuticals
TEVA
$37.3B
| $1.44M | 1.14% |
+31,300
| New | +$1.63M |
|
21
Puma Biotechnology
PBYI
$434M
| $1.43M | 1.13% |
+21,338
| New | +$1.08M |
|
|
RDUS
22
DELISTED
Radius Health, Inc.
RDUS
| $1.39M | 1.1% |
+25,753
| New | +$1.31M |
|
23
CALL
Exelixis
EXEL
$14.1B
| $1.35M | 1.07% |
236,300
+45,600
| +24% | +$493K |
|
|
24
PUT
Bristol-Myers Squibb
BMY
$124B
| $1.31M | 1.04% |
97,200
+47,200
| +94% | +$3.03M |
|
|
YHOO
25
DELISTED
Yahoo Inc
YHOO
| $1.31M | 1.04% |
30,341
| – | – |
|
Similar funds
MC
FIM
TLIC
MKCM
ACM
MFM
VE
GFWEV
FT Options's Q3 2016 Portfolio in Review
As of Q3 2016, FT Options held 493 positions worth $126M, up 8.4% from $116M the previous quarter. Its ten largest holdings account for 38% of the portfolio.
FT Options deployed $224M of net new capital in Q3 2016, opening 153 new positions and adding to 113 existing holdings. Its largest new stake was iShares Biotechnology ETF: 21,000 shares worth $2.03M.
By sector, the portfolio is most concentrated in Healthcare at 40% of assets, down from 41% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
On the sell side, the largest reduction was Apple, an estimated $2.74M trimmed.
- FT Options's largest Q3 2016 buy was iShares Biotechnology ETF: 21,000 shares worth $2.03M.
- FT Options added most to Procter & Gamble in Q3 2016, an estimated $3.82M increase.
- FT Options's biggest Q3 2016 reduction was Apple, cutting an estimated $2.74M.
- FT Options fully exited MEDIVATION, INC. in Q3 2016, selling an estimated $7.18M.
- FT Options's ten largest holdings make up 38% of its $126M portfolio in Q3 2016.
- FT Options opened 153 new positions and closed 127 in Q3 2016.
- FT Options's portfolio value rose 8.4% quarter-over-quarter to $126M.
Based on FT Options's 13F filing for Q3 2016, filed 10 Nov 2016.